Natreon’s Ingredient Sensoril® Ashwagandha has Shown to Provide Benefits for Schizophrenia Patients

Share Article

Adjunctive treatment with Natreon’s Sensoril® ashwagandha root plus leaf extract shown to provide significant benefits for patients with schizophrenia experiencing an exacerbation of symptoms and stress

Natreon is proud to announce that in a randomized, double-blind, placebo-controlled study, researchers at Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, studies whether adjunctive treatment with a standardized extract of W. somnifera roots plus leaves (Sensoril®) improved psychopathology and stress in patients with schizophrenia.

Sixty-six patients with schizophrenia experiencing exacerbation of symptoms were assigned to adjunctive treatment with Sensoril® at 500mg per day for 1 week and thereafter 1000mg per day or placebo for 12 weeks, along with antipsychotic medication. 28 subjects in the Sensoril® arm and 31 subjects in the placebo arm completed the study. Changes from baseline to end of treatment between groups on the Positive and Negative Syndrome Scale, as well as stress and inflammatory markers using the Perceived Stress Scale, S100 calcium-binding protein B (S100B) and C-reactive protein (CRP) were compared.

Beginning at 4 weeks and continuing to the end of treatment, the group treated with Sensoril® achieved significantly greater reductions in negative, general and total symptom scores compared with patients treated with placebo. Effect sizes favoring Sensoril® ranged from large for negative and total symptoms (Cohen d = 0.83) to medium for general symptoms (Cohen d = 0.76). Although positive symptom scores improved more in patients receiving Sensoril® compared with placebo, they did not reach statistical significance. Treatment with Sensoril® also resulted in a greater improvement in stress scores (Cohen d = 0.58) than treatment with placebo. CRP and S100B dropped more in these patients as well, but not significantly compared with placebo.

The study is being replicated at UCLA and University of Maryland, as there is a need for an effective medication for treatment of the negative symptoms in schizophrenia patients.

Dr. Sanni Raju, CEO of Natreon, says that Natreon may pursue medical food application or file a botanical drug application.

About Natreon, Inc.:
Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon’s patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon’s ingredients have been tested in multiple clinical and safety studies to ensure safety, efficacy and authenticity. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India. For more information, visit:

For further information please contact:
Dr. Sanni Raju, CEO/Chairman or Bruce Brown, President
2-D Janine Place
New Brunswick, NJ 08901

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Rohan
Natreon, Inc.
+1 7322961080 Ext: 20
Email >
Like >
Natreon, Inc.

Visit website